500 mg/2 ml powder and solvent for injectable solution for im use
1 g/3,5 ml powder and solvent for injectable solution for im use
1 g/10 ml powder and solvent for injectable solution for ev use
2 g powder for solution for infusion
J01DD04 - Antibacterial for systemic use, third generation cephalosporins
CEFRAG is indicated for the treatment of the following infections in adults and children including term neonates (from birth):
Community acquired pneumonia
Hospital acquired pneumonia
Acute otitis media
Complicated urinary tract infections (including pyelonephritis)
Complicated skin and soft tissue infections
Infections of bones and joints
CEFRAG may be used:
For treatment of acute exacerbations of chronic obstructive pulmonary disease in adults.
For treatment of disseminated Lyme borreliosis (early [stage II] and late [stage III]) in adults and children including neonates from 15 days of age.
For Pre-operative prophylaxis of surgical site infections.
In the management of neutropenic patients with fever that is suspected to be due to a bacterial infection.
In the treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above.
CEFRAG should be administered together with other antibacterial agents where the possible range of causal bacteria does not fall into its spectrum of action.
Refer to the official guidelines for proper use of antibacterial agents.
Magis Farmaceutici S.r.l.
Summary of Product Characteristics - Cefrag 500 mg/2 ml_1 g/3,5 ml
Congresso Nazionale della Società Italiana per lo Studio delle Cefalee